Yesterday, the FDA approved Pfizer’s XELJANZ (tofacitinib) for treatment of RA when methotrexate has failed to work adequately. This oral medicine is in a new class of drugs: Janus kinase (JAK) inhibitor. Another JAK, ruxolitinib, was approved last year for the … Continue reading
Nummular dermatitis (aka discoid eczema) has an incidence of 2 in 1000 people, mostly men in the age range of 55-65. However, treatment with a TNF-inhibitor is also a risk factor. Like many medical terms, the name nummular dermatitis comes from … Continue reading
When I was little, my parents were happy to have money to put food on the table. There wasn’t extra for luxuries. Television was a luxury. Our first TV set was a hand-me-down from a family friend who had just … Continue reading
